Outpatient use of tPA to recanalize thrombosed native fistulas a case series and discussion of literature
Abstract
Background: The present study aims to evaluate the effectiveness of ultrasound-guided percutaneous alteplase (t-PA) injection for the treatment of long segment ( ≥14cm) thrombi in the efferent veins of native arteriovenous fistulas in hemodialysis patients.
Methods: A total of 9 patients who underwent t-PA application under ultrasound guidance in the interventional radiology clinic between 2019 and 2021 were included in the study. During the intervention, information such as thrombosed segment length, t-PA dose, number of sessions, presence of aneurysmal segment, bleeding after the intervention and the need for percutaneous transluminal angioplasty (PTA) were recorded. Restoring the flow in the fistula was considered the successful outcome. All statistical evaluations were performed with the IBM SPSS Statistics 21 software (version 21.0; SPSS Inc, Chicago, Illinois) for Windows.
Results: Mean age of the patients was 48.7±14 years, the fistula age was 28.7±11 months, the thrombosis age was 3.5±2 days, and the thrombosed segment length was 17.7±2.9 cm. Post-intervention bleeding that did not require treatment was encountered in 2 patients, and stenosis in the proximal fistula was encountered in 6 patients. PTA was applied to 7 patients after t-PA. After the interventions, effective flow was provided in all patients.
Conclusion: Ultrasound-guided percutaneous t-PA injection should be considered as an effective intervention which is less invasive, can be performed as an outpatient intervention and has fewer complications, even if the thrombi segments are long (>10 cm). This technique avoids the potential endothelial damage and saves the cost of the mechanical devices.
Keywords
Kaynakça
- 1. Agarwal AK, Haddad N, Boubes K. Avoiding problems in tunneled dialysis catheter placement. Semin Dial 2019; 32(6):535-40.
- 2. Murea M, Geary RL, Davis RP, Moossavi S. Vascular access for hemodialysis: A perpetual challenge. Semin Dial 2019; 32(6):527-34.
- 3. Al-Jaishi AA, Liu AR, Lok CE, Zhang JC, Moist LM. Complications of the Arteriovenous Fistula: A Systematic Review. J Am Soc Nephrol 2017; 28(6):1839-50.
- 4. Coleman CI, Tuttle LA, Teevan C, Baker WL, White CM, Reinhart KM. Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: a meta analysis. Int J Clin Pract 2010; 64(9): 1239-44.
- 5. Swedberg SH, Brown BG, Sigley R, Wight TN, Gordon D, Nicholls SC. Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation 1989; 80(6): 1726-36.
- 6. Dougherty MJ, Calligaro KD, Schindler N, Raviola CA, Ntoso A. Endovascular versus surgical treatment for thrombosed hemodialysis grafts: A prospective, randomized study. J Vasc Surg 1999; 30(6):1016-23.
- 7. Marston WA, Criado E, Jaques PF, Mauro MA, Burnham SJ, Keagy BA.Prospective randomized comparison of surgical versus endovascularmanagement of thrombosed dialysis access grafts. J Vasc Surg 1997; 26(3):373-80; discussion 80-1.
- 8. Gravanis I, Tsirka SE. Tissue-type plasminogen activator as a therapeutic target in stroke. Expert Opin Ther Targets 2008; 12(2):159-70.
- 9. Heiferman DM, Li DD, Pecoraro NC, Smolenski AM, Tsimpas A, Ashley WW Jr. Intra-Arterial Alteplase Thrombolysis during Mechanical Thrombectomy for Acute Ischemic Stroke. J Stroke Cerebrovasc Dis 2017; 26(12):3004-8.
- 10. Islam MS. Thrombolytic Therapy by Tissue Plasminogen Activator for Pulmonary Embolism. Adv Exp Med Biol 2017; 906:67-74.